ASTRAZENNSEAstraZeneca Pharma India Limited· PharmaceuticalsMediumNeutral
Announced Tue, 9 Jun · 17:47 IST

AstraZeneca Pharmaceuticals AB has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Ownership Changes View source PDF

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.0%1-day move
₹8382.50
prior close
₹8480.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.6-0.6-0.5-0.6-2.0-1.8+0.3+1.5+1.7+0.9-1.7-3.2
Up moveDown movePending
AI summary

AstraZeneca Pharmaceuticals AB, the promoter entity of AstraZeneca Pharma India, has submitted a disclosure to the stock exchange under Regulation 31(4) of the SEBI Takeover Regulations. This regulation requires shareholders, especially promoters and persons holding encumbered shares, to disclose details of shares that have been pledged or otherwise encumbered. The filing indicates that there is some change or update related to encumbered shares held by the promoter in AstraZeneca Pharma India. However, the specific nature of the disclosure—whether shares were newly pledged, released, or invoked—is not detailed in the announcement.

Likely market impact

This is a routine regulatory disclosure and may not have a material impact on the stock price. Shareholders should watch for further details from the company regarding any change in pledged shares by the promoter entity.